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Abstract
Apolipoprotein D (ApoD) is an extracellular glycoprotein of the lipocalin protein family, 
involved in different functions such as immune response, cell proliferation regulation, 
chemoreception, retinoid metabolism, axon growth, and proteolysis regulation. This 
lipocalin is expressed predominantly in the nervous system (NS), both prenatally (vascu-
lar pericytes) and postnatally (glia and neurons) and in adulthood. It is also expressed in 
other tissues and is carried by high-density lipoprotein (HDL) in plasma, so it could inter-
fere in cholesterol and other lipids regulation. ApoD increases considerably in systemic 
apocrine gland tumors and also in some primary brain tumors. Although the specific bio-
logical role of ApoD is unknown, the presence of ApoD in tumors appears to be a prog-
nostic factor in their evolution. Regarding the NS, increased ApoD expression observed 
in many neurodegenerative diseases could be used to make an early diagnosis thereof.
Keywords: oxidative stress, apolipoprotein, nervous system, colorectal cancer
1. Introduction
Apolipoprotein D (ApoD) is an extracellular glycoprotein of the lipocalin protein  family, 
involved in different functions such as immune response, cell proliferation regulation, 
chemoreception, retinoid metabolism, axon growth, and proteolysis regulation [1, 2]. This 
lipocalin is expressed predominantly in the nervous system (NS), both prenatally (vascular 
pericytes) and postnatally (glia and neurons) and in adulthood [3, 4]. It is also expressed in 
other tissues and is carried by high-density lipoprotein (HDL) in plasma, so it could interfere 
in cholesterol and other lipid regulation [5].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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ApoD increases considerably in systemic apocrine gland tumors and also in some primary 
brain tumors [6]. Although the specific biological role of ApoD is unknown, the presence 
of ApoD in tumors appears to be a prognostic factor in their evolution. Regarding the NS, 
increased ApoD expression observed in many neurodegenerative diseases could be used to 
make an early diagnosis thereof [6].
Under cellular stress conditions, ApoD presents extra- and intracellular overexpression [7, 8], 
suggesting that it plays a fundamental role in cell proliferation, survival, and death.
2. Structure and metabolism of ApoD
ApoD gene is located on human chromosome 3 and chromosome 16 in rodents. Its amino acid 
sequence does not maintain similarity to other apolipoproteins but is highly similar to some 
members of the lipocalins family [6, 9].
The molecular weight of mature human ApoD is 19 kDa. It consists of 169 amino acids 
with glycosylation sites at residues 45 and 178, corresponding to asparagine. Its molecular 
weight is 32 kDa calculated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and approximately 18% of them are carbohydrates. The glycosylation pattern 
of ApoD varies depending on the site; these values correspond to plasma ApoD, where carbo-
hydrates are less complex and extensive and glycosylation is therefore smaller than ApoD in 
other body secretions and tissues [6].
Secondary structure has been proposed as a small β-barrel structure constituted by eight anti-
parallels β-leaves (Figure 1B). Within this framework, hydrophobic residues are situated in 
Figure 1. Tertiary structure of apolipoprotein D in three-dimensional vision. A. Model of protein surface. The pocket 
where hydrophobic ligands bind is indicated with an arrow. B. Model of α-carbon skeleton of the protein, also showing 
the eight β-chains that constitute the barrel of this lipocalin. Both figures have been set up with the program Weblab 
ViewerLite.
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the inner surface of a central pocket (arrow in Figure 1A). This location would be the binding 
site for the ApoD ligand. Other hydrophobic residues could also participate in the association 
of ApoD with HDL particles [6].
It has been found both on a molecular as gene scale that ApoD is a heterogeneous pro-
tein. It has different isoforms and there is evidence of the presence of two alleles that are 
expressed in a codominant way in a single gene locus. The first fact can be explained, 
partly, by a posttranslational process, consisting sometimes in the addition of sialic acid. 
With respect to the gene, two different alleles were identified by digestion with enzymes 
Taq1 and Msp1.
Population studies show variations in ApoD gene as polymorphisms that may affect the func-
tion of ApoD, the lipoprotein metabolism, and plasma concentrations thereof. In fact, certain 
ApoD gene alleles show a significant correlation with the predisposition to certain neurode-
generative diseases [10].
The ApoD is also found in various mammals, with very similar functions to human ApoD, 
and whose similarity in amino acids is shown in Table 1. But it is found not only in mammals 
but also in birds with even greater similarity to human lipocalin than that of some mammals. 
There are homologous genes in insects and is even located in prokaryotes. In Escherichia Coli, 
there is a lipocalin (Blc) present in the outer membrane of the bacteria that maintain a 31% 
similarity with human ApoD. It is the first lipocalin located in bacteria and its expression 
occurs mainly during the stationary phase interacting with the response to hunger during this 
phase of bacterial cycle.
2.1. Location, synthesis, and expression of ApoD
ApoD has been detected in a variety of organs, tissues, and fluids, reflecting its importance 
and suggesting that it may play different roles depending on the organ in which it is located. 
It has been detected in plasma, tear fluid, in the eye ciliary body, in the cerebrospinal fluid (in 
concentrations without relation to plasma concentration), in the perilymph (in similar concen-
tration to plasma), in the middle ear fluid, in urine, and in sweat [6].
Among the mammals, many interspecific differences in the ApoD expression can be found in 
different organs and tissues (see Table 2).
In contrast to other lipoproteins, the main synthesis of ApoD is not produced in the intes-
tine and liver but in the adrenal glands, kidney, and central nervous system (CNS) [6]. Cells 
expressing as many ApoD mRNAs are perivascular fibroblasts, glial cells, pial and perivascu-
lar CNS, and some neurons [3, 4].
Human Rabbit Guinea pig Rat Mouse E. coli
Human – 80% 78% 69% 71% 31%
Mouse 71% 82.6% – 92.6% – –
Table 1. Similarity of the amino acid sequence in apolipoprotein D found in different species.
Apolipoprotein D
http://dx.doi.org/10.5772/66626
27
2.2. Ligands and functions of ApoD
The ApoD is mainly part (83%) of the high density lipoproteins (HDL) [11], but can also be 
found in small amount in very low-density (VLDL) and low-density lipoproteins (LDLs) [6]. 
As a component of HDL, it was observed that ApoD is associated to cholesterol ester trans-
ferase protein (CETP), to Apo AI or Apo A-II (over 50% of ApoD present in HDL is form-
ing part of these complexes with Apo A-II) [11]. In HDL, ApoD is also forming part of the 
complex responsible for the transport of cholesterol from peripheral tissues to the liver for 
its metabolism, especially with the lecithin-cholesterol acyltransferase (L-CAT). It is believed 
that ApoD could stabilize the enzymatic activity of the L-CAT or act as a substrate or reac-
tion products carrier, such as cholesterol or cholesteryl esters, as an increase in the activity of 
cholesterol esterification by L-CAT in the presence of ApoD has been observed. All this sug-
gests that interactions between cholesterol metabolism and ApoD exist, but there is evidence 
that cholesterol is not the main ligand of ApoD as initially believed. This is supported by the 
low affinity existing between them and by the fact that in the cyst fluid of breast cancer ApoD 
concentration increases up to 1000 times, while cholesterol increases only twice [6].
The ApoD can also be free or bound to other small molecules as it interacts with many ligands 
such as progesterone and other progestins, pregnenolone, bilirubin, arachidonic acid (AA), 
estrogens, androgens, and E-3-methyl-2-hexanoic acid (major component of underarm odor). 
Of all these, ApoD is the molecule that has a higher affinity for arachidonic acid, which make 
us believe that through the L-CAT, ApoD could join in the metabolism regulation,  removing it 
Human Monkey Rabbit Guinea pig Rat Mouse Hamster
Brain + + + + + + +
Liver + + nd + + + −
Kidney + + nd + + - −
Intestine + + nd nd + − −
Pancreas + + nd nd + nd nd
Placenta + nd nd nd nd nd nd
Adrenal + nd + + + + nd
Spleen + + + + + − −
Heart nd nd nd nd + − +
Bladder nd + nd nd + nd nd
Skin nd + nd nd + nd nd
Lung nd nd + + + + nd
Testicles nd + + + + + nd
Ovaries nd nd + + − + nd
+: presence; −: Not present; nd: not determined.
Table 2. Differences in the expression of ApoD in different organs and tissues of several mammals.
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in order to prevent its transformation into cholesterol esters [6]. It is also important to mention 
that other linking molecule is retinoic acid, a molecule that plays a major role in the develop-
ment of nervous system. Indeed, ApoD is the human lipocalin with higher affinity for retinoic 
acid [12].
Belonging to the family of lipocalin and the variety of tissues in which ApoD is expressed, 
Makes us pose the hypothesis that this apolipoprotein is multiligand and multifunction and 
that both function as ligands vary depending on the organ in which it is expressed [6].
2.3. Expression regulation of ApoD
Transcriptional regulation of the expression of ApoD seems to be very complex due to the 
many factors that modulate this protein [13]. Overall, we could say that there are changes 
in cell proliferation which modulate the expression of ApoD, or vice versa. Do Carmo et al. 
have studied in detail the ApoD promoter and determined the genomic region required for 
the induction of ApoD when cell senesces (when the crop exceeds the confluence). In this 
genomic region, there is a purine-pyrimidine fragment alternation and octanucleotide SRE 
(serum-responsive element) that appear to be essential for the induction. Curiously, SRE sites 
are present in sites related to cholesterol and fatty acids metabolism and mediate the regula-
tion of transcription of these genes depending on sterol genes [13].
3. ApoD as a protective agent against oxidative stress
To conclude this section, we note that in studies conducted in animal models (particularly in 
the fruit fly Drosophila melanogaster and the mouse), in which the expression of ApoD has been 
genetically modified, ApoD deficit involves behavioral defects and neuronal death by apop-
tosis. Also, there is less resistance to NS stimuli that induce oxidative stress (OS). Moreover, 
lipocalin overexpression leads to increased resistance to factors which induce increased oxi-
dative stress [14–16].
In summary, ApoD is a protein with multiple functions depending on the location in which it 
is expressed. It is a multiligand protein, but it does not mean that it has a specific role, so many 
studies are still needed to unravel the functional role of ApoD at different levels in which it 
operates. It has an important role in CNS pathologies, as it behaves as an acute phase protein, 
rising in neuronal damage. However, we cannot yet say that it acts as a neuroprotective or 
neurotoxic protein.
We also checked that oxidative stress induces the expression of ApoD in the nervous system 
[14]. This and the fact that many of the diseases mentioned above occur with increased oxida-
tive stress made us think that this lipocalin plays an important role in controlling this stress 
when it occurs in pathological conditions.
Evidence from animal models supports this hypothesis. It is specifically carried out with 
experiments in Drosophila fly and mice. In the fly, the Glial Lazarillo protein (Glaz) is the 
homologous protein to ApoD. In Glaz mutant flies that inactivate its expression, subjected to 
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a stimulus that induces oxidative stress, neuronal death and degeneration are increased. By 
contrast, in flies with excess of ApoD there is a greater resistance to oxidative stress [16]. In 
experiments conducted in knockout ApoD mice (in which the gene is inactivated), we have 
found that these have also a lower resistance to oxidative stress and behavioral changes [17].
4. ApoD in nervous system and its relationship with neurodegenerative 
pathologies
We can find ApoD both in the central nervous system (CNS) and in the peripheral nervous 
system (PNS) and is part of the small group of apolipoproteins that are synthesized in the NS 
close to Apo E, J and C-I [6].
ApoD’s role as a conveyor of lipid molecules suggests that it might play an important role in 
lipid transport during neuronal regeneration [6].
The ApoD accumulates in the peripheral nerve after its injury. Its concentration is much 
higher there than other apolipoproteins and also has been shown to be synthesized locally 
and not from the bloodstream, such as Apo A-I and Apo A-IV. In rat sciatic nerve injury, the 
concentration is increased 500-fold relative to baseline, and mRNA is elevated up to 40 times. 
Its mission might be to transport cholesterol to remyelination and new membrane formation. 
It could also carry bilirubin, which is found in damaged nerves, thereby preventing toxic 
accumulation of the same [6].
In adult animals, ApoD expression is primarily located in the pial and perivascular cells, 
astrocytes and oligodendrocytes and, inconsistently, in neurons [6].
ApoD has been observed attached to oligodendrocytes in the white matter of the human cere-
bral cortex. In the gray matter of young individuals, ApoD expression of both glial cells and 
neurons is limited; this expression increases with normal aging. It seems that ApoD synthesis 
could be linked to the phenomenon of cellular activation in astrocytes, taking place in astro-
gliosis. ApoD is constitutively secreted by mouse astrocyte cultures.
In neurons, labeling studies indicate that ApoD is more abundant in some areas than in oth-
ers. In cerebrum and cerebellum, its labeling is poor and inconsistent, while in the vestibular 
nuclei, bulbar olive and raphe marking are abundant and constant.
In the nervous system, ApoD could participate in the process of regeneration and remyelin-
ation. It has also been proposed as lipids and other substances carrier through the blood-brain 
barrier. It could also play a significant role in maintaining appropriate levels of cholesterol in 
compartments not directly exposed to blood. Finally, as a function of this lipocalin the local 
transport of steroid hormones has also been proposed, which modulate the formation of syn-
aptic connections [6].
4.1. ApoD and nervous injury
The relation between ApoD processes and nerve regeneration has conducted several studies 
in which injuries are reproduced in the CNS. In all of them, an increase in the ApoD marking 
has been observed, quite possibly of a local origin as ApoD concentration in the bloodstream 
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was low. This may be due to the need of increased lipid traffic during the period of recon-
struction and restructuration following serious injuries. However, in a study conducted in 
deficient ApoE mice subjected to hypoxia To cause a stroke, no change was seen in the levels 
of ApoD with respect to wild strains, where this apolipoprotein would not be involved in 
cleaning lipid material in the area of the lesion and not be a part of the compensatory mecha-
nism against the absence of ApoE.
4.2. ApoD and nervous pathologies
There are some nerve pathologies in which ApoD is elevated with respect to normal healthy 
individuals (see Table 3).
4.2.1. Niemann-Pick disease type C
In the mouse, this disease is a hereditary disorder of cholesterol homeostasis, which accumu-
lates in unesterified form in the lysosomes. We found progressive dementia and development 
of neurofibrillary tangles. It was observed that the amount of ApoD in brains of diseased indi-
viduals was greater than that in healthy individuals and it was mainly secreted by astrocytes. 
This suggests ApoD intervention in cholesterol metabolism, acting as a conveyor of lipids 
released in demyelinating disease processes.
4.2.2. Alzheimer’s disease
This disease is a disease of pathology substrate constituent of senile plaques and neurofibril-
lary tangles. These lesions are clinically reflected in a consistent mental decline in dementia, 
disorientation, memory loss, and learning capacity.
In these patients, increased ApoD is found in the hippocampus and CSF compared with 
control subjects. Also, a correlation was found between ApoD and the presence or absence 
of the ApoE4 allele, so that high concentrations of ApoD were interpreted as a compensa-
tory mechanism against the absence of a particular allele of ApoE in nerve regeneration and 
maintenance and CNS repair. The ApoD would act in transporting different substances. This 
theory has been challenged by studies with ApoE-deficient mice in which the expression of 
ApoD was not altered by the absence of ApoE.
Other studies indicate an ApoD increase in the entorhinal and temporal cortex in elderly 
subjects. According to some authors, ApoD could participate in the neurochemical cascade 
associated with chronic CNS neuronal degeneration. Other studies indicate that there is no 
correlation between ApoE and ApoD and both are involved in neurodegeneration in this dis-
ease independently.
Moreover, the analysis of senile plaques and neurofibrillary tangles has resulted in conflict-
ing data, some authors find ApoD presence while in other cases not. This may be due to the 
employed antibodies. In case of ApoD found in senile plaques, ApoD suggests an important 
role in fibrillogenesis and deposition of amyloid peptide. The presence of ApoD in neurofi-
brillary tangles is little or null although we have found a correlation between the number of 
tangles and the amount of ApoD in patients. It has been interpreted as the injured cortical neu-
rons increase the expression of ApoD before tangles accumulate inside. The  concentration of 
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this protein in the hippocampus appears to be related to the severity of intraneuronal neuro-
fibrillary changes, but not with extracellular amyloid peptide level. Thus, the most advanced 
patients (according to the scale of Braak) have a higher content of ApoD.
ApoD has also been located in the vascular preamyloid and amyloid deposits of cerebral amy-
loid angiopathy, present in most Alzheimer's patients and which is common in the elderly. 
These patients are at an increased risk of vascular rupture. An inverse behavior has been 
Pathology/alteration nervous system Overexpression site Detected Increase Ref.
mRNA Protein
Cerebellar ataxia (two mouse models) - Cerebellum + [18]
Unverricht-Lundborg disease (Mouse 
model: progressive ataxia)
- Cerebellum + [19]
Niemann-Pick disease – type C (mouse 
model: progressive neurodegeneration, 
ataxia)
- Cerebellum, fraction myelinated
- Globus pallidus, thalamus, 
substantia nigra. White matter in 
the internal capsule and cerebellum. 
oligodendrocyte precursors
- Brain
+ +
+
[20]
[21]
[22]
Alzheimer’s disease - Cerebral spinal fluid
- Pyramidal neurons with 
granulovacuolar degeneration
- Cortex with neurofibrillary changes
- Hippocampus
- Deposits β-amyloid
+ +
+
+
+
+
[23]
[24]
[25]
[23, 26]
[27]
Schizophrenia and/or bipolar disorder - Blood serum
- Caudate and Brodmann area 9
+
+
[7, 28]
[7]
CNS demyelinating diseases (multiple 
sclerosis)
- Spinal fluid and serum (Intrathecal 
production)
+ [29]
Astrocytomas (pilocytic and other 
noninfiltrating)
- Astrocytoma + + [30]
Transmissible spongiform 
encephalopathies (Mouse)
- Brain + [31]
lethal Sindbis virus encephalitis (mouse) - Central nervous system + [32]
Response to neuroleptic drugs (mouse) - Fluted, globus pallidus, thalamus,  
and white matter
+ + [7, 28, 33]
Neuropathic pain after spinal nerve 
ligation L5 and L6 (rat)
- Dorsal root ganglion + [32]
SNP damage (rat):
- section sciatic nerve
- site of injury
- Fibroblasts in the perineural space +
+ [34]
[35]
CNS damage (rats):
- Entorhinal cortex injury
- Kainic acid in hippocampal CA layer
- Ipsilateral Hippocampus
- Pyramidal neurons in the lesion + +
+
[36]
[37]
Aging under normal conditions - reactive astrocytes in cerebral cortex + + [24, 38, 39]
Table 3. Pathological situations or cell damage which overexpresses the ApoD gene and/or protein accumulates in the SN.
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shown between ApoD and ApoE which would indicate that both proteins have different roles 
in the development of the disease.
It has also been shown the existence of an increased ApoD expression in rats expressing the 
mutated protein of human amyloid peptide precursor (characteristic of this disease). These 
changes were most striking in the hippocampus fimbria, corpus callosum, and other white 
matter tracts. This may represent a compensatory glial response to amyloid peptide deposi-
tion in Alzheimer.
4.2.3. Spongiform encephalopathies
An increase in ApoD expression has been shown, especially in later stages, possibly as a result 
of cellular stress.
4.2.4. Demyelinating diseases
In all of them, the elevation of ApoD is found in CSF, possibly due to rupture of the blood-
brain barrier, but showed an inconstant behavior in relation to the plasma protein levels. In 
multiple sclerosis, there is also an increase in ApoD intrathecal production in the early stages 
of the disease. This has been considered a consequence of demyelination and remyelination 
processes that characterize the disease in the early stages. Also, increased ApoD has been 
described in patients treated with steroid.
4.2.5. Schizophrenia and bipolar disorder
In these psychiatric disorders, the expression of ApoD also increases in serum and brain, acting 
as disease marker. In schizophrenia and schizoaffective disorders, a decrease of arachidonic 
acid is found in the membrane of blood cells, fibroblasts, and brain tissues. We also found cal-
cium-independent phospholipase A2 increased activity in psychiatric illnesses as a decrease of 
calcium-dependent phospholipase A2 activity [7]. It has shown an increase in the expression of 
ApoD in the striatum of rodents treated with clozapine and in various regions of white matter. 
In control animals, ApoD is mainly expressed in astrocytes while in treated animals the increase 
occurred mainly in neurons. This indicates a contribution of ApoD to antipsychotic mechanisms 
of this neuroleptic [6]. In addition, arachidonic acid also increases with treatment [7].
There are regional differences in ApoD expression when comparing schizophrenia with bipo-
lar disorder, whereby ApoD could intervene in a natural response to the targeted effects of 
this neuropathology. In treated patients with schizophrenia, ApoD levels descend compared 
to normal values. The low concentration of ApoD in serum confirms the association of ApoD 
with a systemic deficiency in lipid metabolism. Serum ApoD levels of patients with schizo-
phrenia are greater than those of control subjects, which may indicate the onset of the disease. 
Arachidonic acid (AA) is the precursor of eicosanoid synthesis and prostaglandin metabolism 
and relates to the formation of the second messenger cAMP. ApoD could link to transport 
and union of AA, prevent peroxidation and make it accessible for the synthesis of membrane 
phospholipids, protecting the neuronal membrane functions [7].
Finally, we should note that in studies carried out in animal models (particularly, in the 
D. melanogaster fly and mouse), in which ApoD expression has been genetically modified, 
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the deficit of ApoD involves behavioral defects and neuronal death by apoptosis. Also, 
there is less resistance to SN stimuli that induce oxidative stress. Moreover, lipocalin over-
expression leads to increased resistance to factors which induce increased oxidative stress 
[9, 15, 16].
In summary, ApoD is a protein with multiple functions depending on the location in which 
it is expressed. The fact that it is also multiligand does not allow us to point a specific role 
for this protein; so, many studies are still needed to unravel the functional role of ApoD at 
different levels in which it operates. What we can say is that it has an important role in CNS 
pathologies. We cannot yet determine if it acts as a neuroprotective or neurotoxic protein, but 
we can affirm that it behaves as an acute phase protein, rising in neuronal damage.
4.2.6. ApoD gene polymorphisms
As mentioned earlier, we have determined four gene polymorphisms ApoD in the patients 
in our study.
Polymorphism rs1467282, c.334 + 718T > C in intron 4 of the gene was determined as genetic 
variation ApoD in Alzheimer's disease in Finnish population [10]. The theoretical European 
population frequencies given in Table 4 are as NCBI database—single nucleotide polymor-
phism (http://www.ncbi.nlm.nih.gov/projects/SNP).
The polymorphism rs 5952 c.44T> C showed increase risk of sporadic Alzheimer's disease in 
Chinese population. Rs rs 1568566 haplotype T 5952 C showed lower risk and could be inter-
preted as a protective factor against Alzheimer's disease [40]. No data frequency in European 
population was seen.
With respect to Rs1568565 polymorphism c.124-352A > G  (intron 2), the -352G allele was 
associated with a threefold increase risk of Alzheimer's disease early onset (≤65 years) Finnish 
population [10]. The theoretical European population frequencies given in Table 5 are as NCBI 
database—single nucleotide polymorphism (http://www.ncbi.nlm.nih.gov/projects/SNP):
As we see, ApoD could confer protection against damage in the body by oxidative stress, cer-
tain polymorphisms ApoD could act in these diseases protecting the carriers of said damage. 
That is why we think that variations of this gene may confer susceptibility to damage caused 
by oxidative stress.
Genotype/allele CC CT TT C T
Frequency 0.860 0.116 0.023 0.919 0.081
Table 4. Data of theoretical frequencies of rs1467282 in European population.
Genotype/allele CC CT TT C T
Frequency 0.833 0.125 0.042 0.896 0.104
Table 5. Data of theoretical frequencies of rs1568565 in European population.
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5. Vascular actions of ApoD
As mentioned above, the 1–2% of HDL is formed by ApoD. Likewise, we can say that 83% of 
plasmatic ApoD is found forming part of HDL particles. Thus, it has been found that decreas-
ing ApoD in HDL before it descends in serum increases the risk of stroke. The fact that the 
HDLs are responsible for transporting cholesterol from peripheral tissues to the liver and that 
most ApoDs are present in these lipoproteins makes us think about its beneficial effects from 
the cardiovascular standpoint [11].
The presence of ApoD has been detected in the atheromatous plaque, but not in normal 
coronary arteries [11]. An important finding is the large amount of ApoD in quiescent cells 
[13]. However, its expression is greatly reduced in proliferating cells. In vitro studies show 
that ApoD inhibits cell proliferation, obtaining a similar effect to that produced by calcium 
antagonists, demonstrating its beneficial effects in the cardiovascular field. Also in his role of 
inhibiting proliferation could play an important role in cancer [11].
It has been observed that ApoD is related to the cell migration of vascular smooth muscle for 
closing the ductus arteriosus and the platelet-derived growth factor—BB (PDGF-BB)—may 
mediate its expression and localization. It has also been found that ApoD is necessary for the 
migration of pulmonary artery in response to PDGF-BB.
6. ApoD and tumor pathology
ApoD is associated with reduced proliferative activity of cancer cells, and is abundantly 
raised in senescent cells. In breast cancer, ApoD expression is associated with favorable his-
tology and clinical stage, whereas in adjacent tumor stromal ApoD expression is a marker of 
adverse prognosis. Estrogen receptor expression in breast cancer is inversely related to ApoD 
expression. Therefore, a combined estrogen receptor positivity/ApoD positivity could reflect 
a nonfunctional estrogen receptor pathway, and this subset of breast cancer patients does not 
react to adjuvant tamoxifen treatment [41].
Our group has conducted studies in the field of colorectal cancer (CRC) and ApoD. In CRC, 
tumor growth coincides with increased inflammation, COX-2, and nuclear factor kappa 
B-mediated, which triggers the release of tumor necrosis factor alpha and interleukin-6 [42]. 
This inflammation increment corresponds to increased levels of reactive oxygen species 
(ROS) and their reactive derivatives, inducing in turn oxidative stress (OS) [43–45]. CRC cells 
show an increase in lipid peroxidation by products that could be triggered by the increased 
arachidonic acid levels attained by the increased activity of COX-2 [46, 47]. The accumula-
tion of lipid peroxidation results in cell damage and death. However, cancer cells tend to 
reduce the levels of the ant proliferative cytokine TGF-β1 and the lipid peroxidation adduct 
4-hydroxynonenal (4-HNE) as a way to prevent apoptosis.
We have seen that ApoD is related to protection against oxidative stress. It has also been 
linked to decreased cell proliferation in models [11, 48]. Its expression is regulated by p73 and 
p63, both p53 family members, which is tumor suppressor so that its expression shows an 
inverse correlation with tumor growth [49].
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As we can see, ApoD levels are increased in the oxidative stress as a defense mechanism but in 
turn are reduced in advanced stages of cancer. Our group has studied mechanisms that con-
tribute to this paradox and the influence of ApoD in cancer progression and patient survival.
Our results show a repression of ApoD gene expression in CRC, particularly in the initial 
stages of the disease, which correlates with an elevation of lipid peroxide, adducts in the tis-
sue. In normal mucosa, ApoD protein is present in lamina propria and enteroendocrine cells. 
In CRC, ApoD expression is heterogeneous, with low expression in stromal cells commonly 
associated with high expression in the dysplastic epithelium. ApoD promoter is basally meth-
ylated in HT-29 cells but retains the ability to respond to OS. Exogenous addition of ApoD 
to HT-29 cells does not modify proliferation or apoptosis levels in control conditions, but it 
promotes apoptosis upon paraquat-induced oxidative stress [50].
Our results show ApoD as a gene responding to oxidative stress in the tumor microenviron-
ment. Besides using ApoD as marker of initial stages of tumor progression, it can become a 
therapeutic tool promoting death of proliferating tumor cells suffering oxidative stress [50].
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